Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.

Autor:	Ogilvie GS; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada., van Niekerk D; Lower Mainland Laboratories, Vancouver, British Columbia, Canada.; Cervical Cancer Screening Program, British Columbia Cancer, Vancouver, British Columbia, Canada., Krajden M; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada., Smith LW; Cervical Cancer Screening Program, British Columbia Cancer, Vancouver, British Columbia, Canada., Cook D; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.; Cervical Cancer Screening Program, British Columbia Cancer, Vancouver, British Columbia, Canada., Gondara L; Cervical Cancer Screening Program, British Columbia Cancer, Vancouver, British Columbia, Canada., Ceballos K; Cervical Cancer Screening Program, British Columbia Cancer, Vancouver, British Columbia, Canada., Quinlan D; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Lee M; Cervical Cancer Screening Program, British Columbia Cancer, Vancouver, British Columbia, Canada., Martin RE; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Gentile L; Cervical Cancer Screening Program, British Columbia Cancer, Vancouver, British Columbia, Canada., Peacock S; Cancer Control Research, BC Cancer, British Columbia, Canada.; Canadian Centre for Applied Research in Cancer Control, Vancouver, British Columbia, Canada.; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada., Stuart GCE; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Franco EL; Departments of Oncology and Epidemiology & Biostatistics, McGill University, Montreal, Quebec, Canada., Coldman AJ; Cervical Cancer Screening Program, British Columbia Cancer, Vancouver, British Columbia, Canada.
Jazyk:	angličtina
Zdroj:	JAMA [JAMA] 2018 Jul 03; Vol. 320 (1), pp. 43-52.
DOI:	10.1001/jama.2018.7464
Abstrakt:	Importance: There is limited information about the relative effectiveness of cervical cancer screening with primary human papillomavirus (HPV) testing alone compared with cytology in North American populations. Objective: To evaluate histologically confirmed cumulative incident cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) detected up to and including 48 months by primary HPV testing alone (intervention) or liquid-based cytology (control). Design, Setting, and Participants: Randomized clinical trial conducted in an organized Cervical Cancer Screening Program in Canada. Participants were recruited through 224 collaborating clinicians from January 2008 to May 2012, with follow-up through December 2016. Women aged 25 to 65 years with no history of CIN2+ in the past 5 years, no history of invasive cervical cancer, or no history of hysterectomy; who have not received a Papanicolaou test within the past 12 months; and who were not receiving immunosuppressive therapy were eligible. Interventions: A total of 19 009 women were randomized to the intervention (n = 9552) and control (n = 9457) groups. Women in the intervention group received HPV testing; those whose results were negative returned at 48 months. Women in the control group received liquid-based cytology (LBC) testing; those whose results were negative returned at 24 months for LBC. Women in the control group who were negative at 24 months returned at 48 months. At 48-month exit, both groups received HPV and LBC co-testing. Main Outcomes and Measures: The primary outcome was the cumulative incidence of CIN3+ 48 months following randomization. The cumulative incidence of CIN2+ was a secondary outcome. Results: Among 19 009 women who were randomized (mean age, 45 years [10th-90th percentile, 30-59]), 16 374 (8296 [86.9%] in the intervention group and 8078 [85.4%] in the control group) completed the study. At 48 months, significantly fewer CIN3+ and CIN2+ were detected in the intervention vs control group. The CIN3+ incidence rate was 2.3/1000 (95% CI, 1.5-3.5) in the intervention group and 5.5/1000 (95% CI, 4.2-7.2) in the control group. The CIN3+ risk ratio was 0.42 (95% CI, 0.25-0.69). The CIN2+ incidence rate at 48 months was 5.0/1000 (95% CI, 3.8-6.7) in the intervention group and 10.6/1000 (95% CI, 8.7-12.9) in the control group. The CIN2+ risk ratio was 0.47 (95% CI, 0.34-0.67). Baseline HPV-negative women had a significantly lower cumulative incidence of CIN3+ at 48 months than cytology-negative women (CIN3+ incidence rate, 1.4/1000 [95% CI, 0.8-2.4]; CIN3+ risk ratio, 0.25 [95% CI, 0.13-0.48]). Conclusions and Relevance: Among women undergoing cervical cancer screening, the use of primary HPV testing compared with cytology testing resulted in a significantly lower likelihood of CIN3+ at 48 months. Further research is needed to understand long-term clinical outcomes as well as cost-effectiveness. Trial Registration: isrctn.org Identifier: ISRCTN79347302.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu